Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Acquisitions: 2011-2018

  • Myriad Genetics' Acquisitions was N/A to -$1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $494.6 million, marking a year-over-year change of. This contributed to the annual value of $57.2 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q4 2018, Myriad Genetics' Acquisitions is -$1.1 million, which was down 100.39% from $279.6 million recorded in Q3 2018.
  • Myriad Genetics' Acquisitions' 5-year high stood at $279.6 million during Q3 2018, with a 5-year trough of -$1.1 million in Q4 2018.
  • Its 2-year average for Acquisitions is $123.7 million, with a median of $108.0 million in 2016.